All In Biotech

Drug Trial Radar · NCT05231668

Single Ascending Dose Study of SAR439459 in Adults With Osteogenesis Imperfecta (OI)

A Phase 1b, Single Ascending Dose, Randomized, Double-blind Study to Evaluate the Safety, Tolerability, and Activity of SAR439459 in Adults With Osteogenesis Imperfecta

Last checked: Nov 19, 2026Latest source record: Sep 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

16

Actual

Start

Aug 25, 2022

Primary completion

Nov 12, 2024

Study completion Nov 12, 2024

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Feb 9, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

SAR439459 is a human anti-Transforming growth factor β (TGFβ) monoclonal antibody. This phase 1 clinical study investigates the safety, tolerability, and activity of a single dose of SAR439459 in adult participants with OI. Participants will receive a single IV dose of SAR439459 with safety, pharmacokinetic (PK), and pharmacodynamic (PD) assessments over 24 weeks. There will be up to 3 dose cohorts. In addition to safety, tolerability, and PK assessments, bone mineral density (BMD) will be evaluated by dual-energy Xray absorptimetry (DXA) scan and a series of blood biomarkers will be monitored to document pharmacodynamic effects of the single dose of SAR439459.

Conditions

  • Osteogenesis Imperfecta

Interventions

  • SAR439459Drug

    Powder for solution for infusion; IV infusion

  • PlaceboDrug

    Solution for infusion; IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with adverse events (AEs)/treatment-emergent adverse events (TEAEs)Time frame: From baseline to Week 24

Locations

13 sites in 4 countries. Site status is shown where the registry gives one.

  • UCLA Health_Site Number: 8400006

    Los Angeles, California

  • Yale University - Site Number:8400007

    New Haven, Connecticut

  • Indiana University School of Medicine_Site Number: 8400002

    Indianapolis, Indiana

  • Kennedy Krieger Institute_Site number 8400004

    Baltimore, Maryland

  • Cincinnati Children's Hospital Medical Center Site Number : 8400010

    Cincinnati, Ohio

  • Vanderbilt University Site Number : 8400011

    Nashville, Tennessee

  • Baylor College of Medicine - Site Number:8400003

    Houston, Texas

  • Westmead Hospital_Site Number :0360003

    Westmead, New South Wales, Australia

  • Department of Medicine/ School of Clinical Sciences at Monash Health Monash University_246 Clayton Road_Site Number :0360002

    Clayton, Victoria, Australia

  • Toronto general Hospital_Site Number :1240002

    Toronto, Canada

  • Bone Research and Education Centre_Site Number :1240003

    Oakville, Ontario, Canada

  • Hopital Edouard Herriot _Site Number :2500002

    Lyon, France

  • Hopital Lariboisiere_Site Number :2500001

    Paris, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.